• Corpus ID: 20547092

[The treatment of ENT phlogosis: seaprose S vs. nimesulide].

@article{Antonelli1993TheTO,
  title={[The treatment of ENT phlogosis: seaprose S vs. nimesulide].},
  author={Amanda Antonelli and A Cimino and Arturo di Girolamo and P. Filippi and S Filippin and G. Galetti and Carlo Marchiori and Laetitia Marcucci and Eugenio Mira},
  journal={Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale},
  year={1993},
  volume={13 Suppl 39},
  pages={
          1-16
        }
}
  • A. Antonelli, A. Cimino, E. Mira
  • Published 1993
  • Medicine
  • Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale
In the present multicentre study, the antiphlogistic activity of seaprose S was assessed according to an experimental design of the controlled type versus nimesulide in patients with phlogistic pathology of ENT relevance and in patients undergoing otoiatric surgical operations. One hundred and sixty patients (87 M, 73 F) were treated with seaprose S in 30 mg tablets (3tab/day) while 160 patients (95 M, 65 F) were treated with nimesulide in 100 mg (2 tab/day). The treatment lasted 7 days. At the… 
Current status of the therapeutic uses and actions of the preferential cyclo-oxygenase-2 NSAID, nimesulide
Abstract.This review summarizes the principal therapeutic responses to the preferential COX-2 NSAID, nimesulide, in treating musculo-skeletal joint symptoms and various acute and chronic pain
A case of IgE‐mediated allergy and cell‐mediated allergy to Seaprose‐S in the same patient
TLDR
Seaprose-S is used to correct mucostasis and to improve the clearance of mucus in several pulmonary diseases, such as chronic bronchitis and bronchiectasis by antagonizing inflammation induced by different biochemical substances.
Review Nimesulide: Some Pharmaceutical and Pharmacological Aspects—An Update
TLDR
Initial general clinical experience with selective COX‐2 inhibitors appears to show that they are particularly promising in individuals at risk because of renal diseases, hypertension or congestive heart failure.